Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie 
Welcome,         Profile    Billing    Logout  
 19 Diseases   1 Trial   1 Trial   3388 News 


«12...3132333435363738394041...4849»
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    [VIRTUAL] Piecing together the patient puzzle: navigating the MDR Gram-negative infection treatment paradigm () -  May 8, 2021 - Abstract #ECCMID2021ECCMID_527;    
    pneumoniae. Organized by Pfizer The aims of this sessions are:- To highlight the importance of early adequate therapy for multidrug-resistant (MDR) Gram-negative infection against the backdrop of high patient mortality rates and risk factors for infection- To put a spotlight on problem MDR Gram-negative pathogens, with a focus on Pseudomonas aeruginosa and carbapenem-resistant Enterobacterales (CRE), and the urgent need to optimise treatment against them- To challenge the use of existing standard-of-care therapies, addressing issues such as the need for alternatives to colistin and carbapenems- To share recent updates in the treatment landscape for MDR Gram-negative infection, including recent entrants to the market, and the latest guidance to support their appropriate use- To review the broad-spectrum coverage of ceftazidime–avibactam versus alternative therapies and share the real-world susceptibility and clinical evidence supporting the use of ceftazidime–avibactam
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Enrollment closed, Real-world evidence, Real-world, Gram negative:  Retrospective Analysis of Real World Use of Ceftazidime-avibactam in the Management of Gram Negative Infections (clinicaltrials.gov) -  May 5, 2021   
    P=N/A,  N=500, Active, not recruiting, 
    The absence of the ASP activity has been reflected in the prescription of restricted use antibiotics with a significant increase, with no difference in patients in terms of severity. Not yet recruiting --> Active, not recruiting
  • ||||||||||  sirolimus / Generic mfg.
    [VIRTUAL] FEVER AND CHOLESTASIS IN A MULTIVISCERAL TRANSPLANT RECIPIENT (Hall 02) -  May 4, 2021 - Abstract #ESPID2021ESPID_587;    
    He received a second multivisceral transplant 4 years ago (in treatment with sirolimus and corticosteroids) because of short bowel syndrome...In this episode, empirical treatment with meropenem, colistin and vancomycin was started, and other options were considered in case of no response or resistance to treatment, such as cefiderocol or ceftazidime-avibactam-aztreonam combination as a last option...Key Learning Points When we have few active antibiotics against the causative microorganism, we could consider the use of new antibiotics, however more studies are needed to determine their effectiveness and penetration. This case highlights the importance of controlling the source of infection as part of the treatment.
  • ||||||||||  meropenem / Generic mfg.
    [VIRTUAL] Extended spectrum beta-lactamase heterogeneity in urinary pathogens () -  Dec 26, 2020 - Abstract #ASHP2020ASHP_2719;    
    Higher achievable drug exposures due to urinary excretion, may alter our pharmacodynamic view of antimicrobials even when categorical resistances are factored. Further evaluation with expanded resistance profiling and physiologically based pharmacokinetic estimations should be considered for antimicrobials.
  • ||||||||||  Clinical, Review, Journal:  Carbapenem-Resistant Gram-Negative Infections in Children. (Pubmed Central) -  Dec 23, 2020   
    The availability of pediatric pharmacokinetics and safety data is the cornerstone to broaden the use of proposed agents in adults to the pediatric population. This article provides a comprehensive review of the current knowledge regarding infections caused by CRO with a focus on children which includes epidemiology, risk factors, outcomes and antimicrobial therapy management, with particular attention to new antibiotics.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  A Dimer, but not Monomer, of Tobramycin Potentiates Ceftolozane against MDR/XDR Pseudomonas aeruginosa and Delays Resistance Development. (Pubmed Central) -  Dec 23, 2020   
    Ceftolozane-tazobactam is a potent β-lactam/β-lactamase inhibitor combination approved for the treatment of complicated intraabdominal and complicated urinary tract infections and, more recently, the treatment of hospital-acquired and ventilator-associated bacterial pneumonia...This combination is also more potent than a standard ceftazidime-avibactam combination against these isolates...Susceptibility and checkerboard studies were assessed using serial 2-fold dilution assays, following CLSI guidelines. This strategy provides an avenue to further preserve the clinical utility of ceftolozane and enhances its spectrum of activity against one of the most difficult-to-treat pathogens in hospitals.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Contepo (ZTI-01) / Nabriva, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Clinical, Journal:  Pharmacotherapeutic advances for recurrent urinary tract infections in women. (Pubmed Central) -  Dec 16, 2020   
    Cefepime, Piperacillin-Tazobactam, Ceftolozane-Tazobactam, and Ceftazidime-Avibactam are justified options. Oral therapy with Pivmecillinam, Fosfomycin, and Nitrofurantoin can be used against uncomplicated UTIs due to ESBL infection.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Clinical, Journal:  Ceftazidime/avibactam neurotoxicity in an adult patient with normal renal function. (Pubmed Central) -  Dec 8, 2020   
    The brain MRI-supported meningeal inflammation, along with the increase in blood-CSF-barrier permeability detected on the CSF analysis, could have paved the way for the drug's neurotoxicity by increasing its CNS entering (the CSF CAZ-AVI level in our patient was higher than the highest value reported in a study on children with meningitis). Neurotoxicity of CAZ-AVI and, by analogy, of other cephalosporins should be recognized as a potential adverse effect even in patients with normal renal function, with an increased risk of severe encephalopathy.
  • ||||||||||  Zerbaxa (ceftolozane /tazobactam) / Merck (MSD), Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Journal:  Use of Ceftazidime-Avibactam and Ceftolozane-Tazobactam After Lung Transplantation. (Pubmed Central) -  Dec 2, 2020   
    Neurotoxicity of CAZ-AVI and, by analogy, of other cephalosporins should be recognized as a potential adverse effect even in patients with normal renal function, with an increased risk of severe encephalopathy. CEF-AVI and CEFT-TAZ seems to be effective in treatment of infections caused by MDR bacteria after lung transplant.
  • ||||||||||  Contepo (ZTI-01) / Nabriva, Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Preclinical, Journal, Combination therapy:  In Vitro Activity of Ceftazidime/Avibactam Alone and in Combination With Fosfomycin and Carbapenems Against KPC-producing Klebsiella Pneumoniae. (Pubmed Central) -  Dec 1, 2020   
    The aim of this study was to evaluate the in vitro susceptibility of CAZ-AVI alone and in combination with fosfomycin and carbapenems against KPC-Kp clinical isolates by E-test method. The combination of CAZ-AVI with carbapenems showed synergistic activity, whereas with fosfomycin showed addictive activity, suggesting that fosfomycin may be a carbapenem-sparing strategy in antimicrobial stewardship programs.
  • ||||||||||  Leustatin (cladribine) / J&J, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
    [VIRTUAL] TRICOLEUCEMIA AND MELANOMA: A RARE CASE WITH DIFFICULT THERAPEUTIC MANAGEMENT IN THE PANDEMIC CONTEXT BY THE CORONAVIRUS () -  Nov 26, 2020 - Abstract #HEMO2020HEMO_191;    
    Therefore, it is a patient with a diagnosis of tricoleukemia who developed scalp melanoma in the context of a coronavirus pandemic. In this report, we will discuss the diagnostic and therapeutic approach in view of the concomitant presence of 2 or more neoplasms with related origin (BRAF V600E mutation) and the implications of the coronavirus pandemic in the treatment of hematological neoplasms.
  • ||||||||||  meropenem / Generic mfg., Daewon Pharmaceutical
    [VIRTUAL] A NEAR DRESS EXPERIENCE () -  Nov 21, 2020 - Abstract #ACAAI2020ACAAI_635;    
    As such, a more conservative approach with withholding high-risk antibiotics was reasonable at first, until further data was obtained several months later. Keeping a log of interventions and blood counts over time is an invaluable tool in the evaluation for hypereosinophilia.
  • ||||||||||  Zavicefta (ceftazidime/avibactam) / Pfizer, AbbVie
    Review, Journal:  Selecting the dosage of ceftazidime-avibactam in the perfect storm of nosocomial pneumonia. (Pubmed Central) -  Nov 19, 2020   
    P3
    Keeping a log of interventions and blood counts over time is an invaluable tool in the evaluation for hypereosinophilia. This work serves as a successful practical example of dosage design for a new antibacterial drug therapy in the indication of NP, including VAP, where previous drug therapies have failed, possibly as a result of evaluation of too few variables, thereby limiting the accuracy of pharmacodynamic predictions.